KANTUM DIAGNOSTICS INC (DBA KANTUM BIO)
SAVING LIVES THROUGH EARLY DETECTION AND TREATMENT OF ACUTE KIDNEY INJURY
Acute Kidney Injury (AKI) affects over 4 million people each year in the US, and costs more than $10 billion. Kantum Bio has identified UDP-glucose (UDP-G) as an early biomarker for AKI. UDP-G outperforms any other AKI biomarkers. Kantum Bio has also identified a molecule that can be developed into a new drug for AKI. The annual market opportunity for AKI diagnostics and therapy represents several billions of dollars worldwide.